Clinical trials in cancer screening, prevention and early diagnosis (SPED): a systematic mapping review.

Autor: O'Dowd EL; Department of Respiratory Medicine, Nottingham University Hospitals NHS Trust, Hucknall Road, Nottingham, NG5 1PB, UK. emma.odowd@nottingham.ac.uk., Merriel SWD; Centre for Primary Care & Health Services Research, University of Manchester, Oxford Road, Manchester, M13 9PL, UK., Cheng VWT; Leeds Institute of Medical Research, University of Leeds, Leeds, UK., Khan S; Leicester Cancer Research Centre, University of Leicester, Leicester, LE2 7LX, UK., Howells LM; Leicester Cancer Research Centre, University of Leicester, Leicester, LE2 7LX, UK., Gopal DP; Primary Care Unit, Centre for Primary Care, Wolfson Institute of Population Health, Queen Mary University, London, UK., Roundhill EA; Children's Cancer Research Group, Leeds Institute of Medical Research, University of Leeds, Leeds, UK., Brennan PM; Translational Neurosurgery, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK., Crosbie PAJ; Division of Infection, Immunity & Respiratory Medicine, University of Manchester, Manchester, UK.; Thoracic Oncology Centre, Manchester University NHS Foundation Trust, Manchester, UK., Neal RD; Exeter Medical School, St Luke's Campus, University of Exeter, 1.12 College House, Magdalen Road, EX1 2LU, Exeter, UK., Brown K; Leicester Cancer Research Centre, University of Leicester, Leicester, LE2 7LX, UK., Crosbie EJ; Department of Obstetrics and Gynaecology, St Mary's Hospital, Manchester University NHS Foundation Trust, Oxford Road, Manchester, M13 9WL, UK.; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Oxford Road, Manchester, M13 9WL, UK., Baldwin DR; Department of Respiratory Medicine, Nottingham University Hospitals NHS Trust, Hucknall Road, Nottingham, NG5 1PB, UK.
Jazyk: angličtina
Zdroj: BMC cancer [BMC Cancer] 2023 Sep 04; Vol. 23 (1), pp. 820. Date of Electronic Publication: 2023 Sep 04.
DOI: 10.1186/s12885-023-11300-8
Abstrakt: Background: Global annual cancer incidence is forecast to rise to 27.5 M by 2040, a 62% increase from 2018. For most cancers, prevention and early detection are the most effective ways of reducing mortality. This study maps trials in cancer screening, prevention, and early diagnosis (SPED) to identify areas of unmet need and highlight research priorities.
Methods: A systematic mapping review was conducted to evaluate all clinical trials focused on cancer SPED, irrespective of tumour type. The National Cancer Research Institute (NCRI) portfolio, EMBASE, PubMed and Medline were searched for relevant papers published between 01/01/2007 and 01/04/2020. References were exported into Covidence software and double-screened. Data were extracted and mapped according to tumour site, geographical location, and intervention type.
Results: One hundred seventeen thousand seven hundred one abstracts were screened, 5157 full texts reviewed, and 2888 studies included. 1184 (52%) trials focussed on screening, 554 (24%) prevention, 442 (20%) early diagnosis, and 85 (4%) a combination. Colorectal, breast, and cervical cancer comprised 61% of all studies compared with 6.4% in lung and 1.8% in liver cancer. The latter two are responsible for 26.3% of global cancer deaths compared with 19.3% for the former three. Number of studies varied markedly according to geographical location; 88% were based in North America, Europe, or Asia.
Conclusions: This study shows clear disparities in the volume of research conducted across different tumour types and according to geographical location. These findings will help drive future research effort so that resources can be directed towards major challenges in cancer SPED.
(© 2023. BioMed Central Ltd., part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje